



Global equities enjoyed very strong performance in the first half of 2024. The Vermeer Global Fund rose by 15.3% compared to the IA Global Sector which increased 8.6%. Returns over the first half for the Fund were aided by strong performance from a number of our larger positions and thematic ideas. During June, the Vermeer Global Fund returned 2.7%, in line with global equity markets.

June ended a quarter for equities that was defined by a continued narrowing of market performance. During the second quarter, the average US equity was down 3%, while the S&P 500 was up nearly 4%, with growth equities further outperforming the index. US equities now account for around 72% of the global market while the largest 6 companies make up nearly 22% of the index. While the Fund has material positions in some of these mega-cap stocks, we remain underweight these names overall and have been reducing our weightings so far this year.

At the end of 2023 equities had performed strongly on the back of anticipated US interest rate cuts that were fuelled by dovish remarks from Fed Chair Jerome Powell at the final FOMC meeting of the year in December. Markets quickly moved to price in as many as six rate cuts, and none have as yet materialised. However, global stocks have managed to ignore this disappointment as the US economy has proved more resilient than expected and full year GDP growth is forecast to be around 2.5%. Expectations are still that there may be two rate cuts in late 2024 and we do see some signs from more recent economic data that the US economy has cooled, and consumer spending is weakening.

Over June the top five contributors to return were Oracle, Nvidia, Microsoft, Novo Nordisk and Eli Lilly. The top five detractors to return were Cameco, Carl Zeiss Meditec, Toyota Motor, Orange and Zimmer Biomet.

The continued sluggishness of the Chinese economy has impacted a number of our companies, especially in the health care sector. Danaher, which we have held for many years, expressed confidence that its biologics business would improve towards the end of the year as China bottoms out and the impact of the Inflation Reduction Act on drug development will also start to reduce. We have used weakness in the biologics sector to introduce Thermo Fisher Scientific as a new position in the portfolio, a business we have long admired but never previously owned. We think Thermo, like Danaher, is superbly managed, has a great track record on acquisitions and that current weakness is a great opportunity to accumulate shares as they head into what we believe will be a stronger 2025/26.

Our new position in Shin-Etsu Chemical reflects our desire to increase our exposure to the semiconductor space without buying something that has been totally correlated to the exponential rise in stocks like Nvidia. Shin-Etsu is a Japanese business which has world leading technology in the production of semiconductor silicon and photomasks so effectively is a key part of the supply chain for the industry hiding inside a chemical company. This inevitably impacts the rating the stock trades on but as we see increased demand for powerful chips, we expect Shin-Etsu to be a structural winner and distract attention away from the lowlier rated and lower returning more cyclical parts of the business, including the manufacturing of PVC.

We have increased our cash weighting in the portfolio to around 9%, which reflects a slightly more cautious view of the market, notably in the US after such a strong run. However, we do still see a number of attractive opportunities in new and existing ideas as the rise in the market has been very narrow recently and many stocks are actually down over the first half, despite global equity markets rising over 12%.

*Disclaimer: This is a marketing document. Further information about Vermeer UCITS ICAV including the current Prospectus and Key Investment Information Documents ("KIIDs") are available in English and can be found at [www.vermeer.london](http://www.vermeer.london). Past performance may not be a reliable guide to future performance. Investments can go down as well as up and therefore the return on investment will necessarily be variable. Income may fluctuate in accordance with market conditions and taxation arrangements. Changes in exchange rates may have an adverse effect on the value, price or income of the product. Vermeer Investment Management Limited is authorised and regulated by the Financial Conduct Authority (Financial Register Number 710280) and is incorporated in the United Kingdom (Company Number 09081916). Registered Office Address: 130 Jermyn Street, London, SW1Y 4UR. Vermeer UCITS ICAV ("the Fund") is registered with the Central Bank of Ireland as an open-ended umbrella-type Irish collective asset management vehicle with variable capital (Register Number C154687). Opinions expressed whether specifically or in general or both on the performance of individual securities and in a wider economic context represent our view at the time of preparation. They are subject to change and should not be interpreted as investment advice. This document is intended for use by shareholders of the Fund, persons who are authorised to carry out investment business, professional investors and those who are permitted to receive such information. Nothing in this document should be construed as giving investment advice or any offer, invitation or recommendation to subscribe to the Fund. Any decision to subscribe should be based on the Fund's current Prospectus and KIIDs. Waystone Management Company (IE) Limited, as UCITS Man Co, has the right to terminate the arrangements made for the marketing of funds in accordance with the UCITS Directive. A summary of investor rights policies can be found at <https://www.waystone.com/waystone-policies/>*